ZAS Pharma Ltd. is pleased to announce the successful registration of Venetoclax 100 mg Tablets in Costa Rica, a rapidly developing Central American country – marking another milestone in the company’s global expansion.
Following the registration, ZAS Pharma also successfully secured its first tender for Venetoclax in Costa Rica, reinforcing the company’s growing presence in the Latin American oncology market.
This achievement reflects ZAS Pharma’s continued commitment to expanding access to high-quality specialty oncology medicines and strengthening its international footprint through strategic partnerships and sustainable growth.
